Efficacy and safety of oral desloratadine (10mg once daily) in patients with chronic spontaneous urticaria

17^th International Conference on Dermatology and Cosmetic Medicine & 3^rdGlobal Summit on Heart Congress & 6^th International Conference on Plastic Surgery and Aesthetic Practices

August 08, 2022 Zurich, Switzerland | Hybrid Event

Gabhane M*, Kapadia S, Nageswaramma S, Shah K, Singh A, Mahajan SC, Deshpande A, Chakraborty S, Kar BR, Padmaja P, Bharija SC, Doshi M, Dhawan S, Thavkar A, Rohira P and Lakhwani L

India Medical Affairs, Sun Pharma, Mumbai, India
Kanoria Hospital & Research Centre, Gandhinagar, India
Government General Hospital, Guntur, India
Medilink Hospital Research Centre, Ahmedabad, India
SMS Hospital, Jaipur, India
Supe Heart & Diabetes Hospital & Research Centre, Nashik, India
Oyster & Pearl Hospital, Pune, India
R.G. Kar Medical College & Hospital, Kolkata, India
IMS and SUM Hospital, Bhubaneswar, India
Osmania General Hospital, Hyderabad, India
Sir Ganga Ram Hospital, New Delhi, India
India Clinical Research, Sun Pharma, Mumbai, India

Scientific Tracks Abstracts: J Dermatol Dis

Abstract :

Purpose: Chronic spontaneous/idiopathic urticaria (CSU/CIU) impairs quality of life and affects performance at work/school. Second-generation H1-antihistamines are recommended as first-line treatment for CSU. Updosing (upto 4 times) is recommended in patients unresponsive to the standard dose. This study evaluated efficacy and safety of desloratadine 10mg in the treatment of CSU. Methodology: A multi-centric, open-label, single-arm, phase 3 study was conducted in India in adult patients with moderate-to-severe CSU, active CSU ≥3 weeks, wheals present for ≥3 days/week and not responding to ≥2 weeks of desloratadine 5mg . Desloratadine 10mg was administered orally once daily for 4 weeks. Study assessments included weekly Urticaria Activity Score (UAS7) and Chronic Urticaria Quality-of-Life Questionnaire (CU-Q2oL). Results: Total 256 patients (mean age: 35.3 years) were enrolled in the study. Desloratadine 10mg led to a significant improvement as early as at week 2. Significant improvement by 42.32% (p<0.0001) was seen in mean UAS7 at week 4 (18.17) compared to baseline (31.90). The mean CU-Q2oL score improved by 38.48% from baseline (59.81) to week 4 (35.36) (p<0.0001). By week 4, 21% of patients improved to mild urticaria (UAS7=7-15) and 10% of patients were either well controlled or urticaria free (UAS7=0-6). Adverse events reported in 5.5% of patients were mostly mild (80%), non-serious and did not lead to discontinuation. Two events (0.8%) of dry mouth were reported. Somnolence/ drowsiness was not reported in this study. Conclusion: Desloratadine 10mg once daily was efficacious and well tolerated in patients with moderate-to-severe CSU nonresponsive to standard dose desloratadine. (Study registration number: CTRI/2017/10/010146)

Biography :

Dr Mukesh Gabhane has completed his graduation in Bachelor of Medicine and Bachelor of Surgery (MBBS) from the Maharashtra University of Health Sciences (MUHS), Nashik, followed by MBA (pharmaceuticals) from Narsee Monjee Institute of Management Studies, Mumbai. He has experience of over a decade working in medical affairs (medico-marketing, pharmacovigilance and clinical studies).